Back to BPC-157

Timing & pharmacokinetics

How long does BPC-157 take to work?

Onset timing for BPC-157 varies in the clinical literature. Onset timing is not well-quantified in our dataset — refer to clinical citations on the main entry.

Onset

Half-life

Duration

Timing

AM/evening

Key facts

typical dose
0.2–0.5 mg
dose frequency
1-2 doses
timing
AM/evening
with food
n/a
safety score
2/5
evidence grade
C
class
peptide
PubMed citations
110
legal status (US)
Research-chemical category
legal status (UK)
Research-chemical category
legal status (EU)
Research-chemical category
legal status (AU)
Research-chemical category
restrictions
WADA (S0)
primary mechanism
Stimulates angiogenesis (new blood vessel formation) at injury sites, modulates nitric oxide and growth hormone receptor signalling, and increases collagen production in fibroblasts.

Onset window

BPC-157 onset times in the published literature vary widely. Refer to the citations on the main BPC-157 entry for compound-specific pharmacokinetic data.

Food effect:

Half-life and dosing frequency

Half-life is not characterised in our dataset.

Acute vs. chronic effect

Some nootropics work the first time you take them (BPC-157 may or may not). Others — adaptogens, racetams, and most botanicals targeting BDNF or NGF pathways — require 2–4 weeks of daily dosing before the full effect emerges.

If you don’t feel anything after a single dose and the compound is in the chronic-effect category, that is normal — extend the trial to 2–4 weeks before evaluating. If it is in the acute category and you feel nothing, consider dose, vendor sourcing, or whether the compound matches your goal.

Protocol note from the BPC-157 entry

Subcutaneous research use. Not approved for human consumption.

Mechanism, safety, and citations for BPC-157 are on the main reference page — see BPC-157. For full dose protocol see BPC-157 dosage. To check for stack-level pharmacokinetic conflicts, use the interaction checker.

Onset and pharmacokinetic data reflect the published literature for healthy adults at typical doses. Individual variation in absorption, metabolism (CYP genotype), and gut transit can shift onset by ±50%. This page is informational and not medical advice. See our full disclaimer.